SELLAS Life Sciences (NASDAQ:SLS) says REGAL trial enrollment is slower than anticipated—potentially reflecting durable GPS benefit—and will announce the 80th event before topline results and enter a quiet period; the company holds $107.1M, raised $28.7M via warrants, updated executive terms, and faces takeover chatter tied to timing of final data.
Previous Week Recap
- Regal Trial Enrollment Slower: SELLAS (SLS) says REGAL trial enrollment is slower than expected. Company will announce the 80th event before topline results and enter a quiet period. Slower accrual may reflect durable GPS benefit.
- Cash Increased; Severance Terms Updated: Sellas Life Sciences (SLS) disclosed $107.1M cash at quarter end, raised $28.7M via warrant exercises in April–May, and updated executive severance and change‑of‑control terms.
- Takeover chatter Surrounds SLS: Traders note takeover chatter around SELLAS Life Sciences (SLS), naming big pharmas as potential buyers; timing of SLS’s final data readout is cited as linked to recent stock moves.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.